Top

Archives of Osteoporosis

Published in:

01-12-2021 | Benign Paroxysmal Positional Vertigo | Original Article

Relationship between osteoporosis and benign paroxysmal positional vertigo based on evidence-based medicine and bioinformatics

Authors: Tuanmao Guo, Yanli Xing, Haiyun Zhu, Lan Yang, Yuan Xiao, Jiang Xu

Published in: Archives of Osteoporosis | Issue 1/2021

Abstract

Summary

It has been reported that osteoporosis is a possible risk factor of benign paroxysmal positional vertigo (BPPV).

Purpose

We analyzed the correlation between osteoporosis and BPPV and the possible mechanism by performing evidence-based medicine meta-analysis and bioinformatics analysis.

Methods

Initially, English articles related to osteoporosis and BPPV were obtained through PubMed and EMBASE databases. Stata12.0 software was used for meta-analysis to calculate the odd ratio (OR) and 95% confidence interval (CI) of outcome indicators, and the heterogeneity was evaluated by subgroup analysis, publication bias evaluation, and sensitivity analysis. In addition, microarray datasets related to BPPV and osteoporosis were obtained from gene expression omnibus (GEO) database to screen differentially expressed genes. At last, a mouse model of osteoporosis was established by bilateral oophorectomy for validation. RT-qPCR and Western blot analysis were performed to determine expression of related factors in mouse tissues.

Results

Osteoporosis was suggested as an important risk factor for BPPV through meta-analysis of these 12 articles. It was found that PPP2CA was upregulated in BPPV and low bone mineral density (BMD) samples. Moreover, PPP2CA induced dephosphorylation of BCL2, which may be involved in BPPV through regulation of BMD. Through this mechanism, silencing of PPP2CA could elevate the incidence of BPPV by promoting bone remodeling and reducing the density of otoconia around the macula.

Conclusions

PPP2CA reduces BMD expression by inducing dephosphorylation of BCL2, which may be one of the mechanisms responsible for the onset of BPPV in osteoporosis.

Available only for authorised users

Ensrud KE, Crandall CJ (2017) Osteoporosis. Ann Intern Med 167:ITC17-ITC32. https://doi.org/10.7326/AITC201708010

Marcucci G, Brandi ML (2015) Rare causes of osteoporosis. Clin Cases Miner Bone Metab 12:151–156. https://doi.org/10.11138/ccmbm/2015.12.2.151

Compston JE, McClung MR, Leslie WD (2019) Osteoporosis Lancet 393:364–376. https://doi.org/10.1016/S0140-6736(18)32112-3CrossRefPubMed

Kopecky SL, Bauer DC, Gulati M, Nieves JW, Singer AJ, Toth PP, Underberg JA, Wallace TC, Weaver CM (2016) Lack of evidence linking calcium with or without vitamin d supplementation to cardiovascular disease in generally healthy adults: a clinical guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology. Ann Intern Med 165:867–868. https://doi.org/10.7326/M16-1743CrossRefPubMed

Mezuk B (2008) Affective disorders, bone metabolism, and osteoporosis. Clin Rev Bone Miner Metab 6:101–113. https://doi.org/10.1007/s12018-009-9025-yCrossRefPubMedPubMedCentral

Kim JS, Zee DS (2014) Clinical practice. Benign paroxysmal positional vertigo. N Engl J Med 370:1138–1147. https://doi.org/10.1056/NEJMcp1309481CrossRefPubMed

Balatsouras DG, Koukoutsis G, Fassolis A, Moukos A, Apris A (2018) Benign paroxysmal positional vertigo in the elderly: current insights. Clin Interv Aging 13:2251–2266. https://doi.org/10.2147/CIA.S144134CrossRefPubMedPubMedCentral

Jeong SH, Kim JS (2019) Impaired calcium metabolism in benign paroxysmal positional vertigo: a topical review. J Neurol Phys Ther 43(Suppl 2):S37–S41. https://doi.org/10.1097/NPT.0000000000000273CrossRefPubMed

Vibert D, Sans A, Kompis M, Travo C, Muhlbauer RC, Tschudi I, Boukhaddaoui H, Hausler R (2008) Ultrastructural changes in otoconia of osteoporotic rats. Audiol Neurootol 13:293–301. https://doi.org/10.1159/000124277CrossRefPubMed

10.

Morita K, He S, Nowak RP, Wang J, Zimmerman MW, Fu C, Durbin AD, Martel MW, Prutsch N, Gray NS, Fischer ES, Look AT (2020) Allosteric activators of protein phosphatase 2A Display Broad Antitumor Activity Mediated By Dephosphorylation of MYBL2. Cell 181(702–715):e720. https://doi.org/10.1016/j.cell.2020.03.051CrossRef

11.

Reynhout S, Jansen S, Haesen D, van Belle S, de Munnik SA, Bongers E, Schieving JH, Marcelis C, Amiel J, Rio M, McLaughlin H, Ladda R, Sell S, Kriek M, Peeters-Scholte C, Terhal PA, van Gassen KL, Verbeek N, Henry S, Scott Schwoerer J, Malik S, Revencu N, Ferreira CR, Macnamara E, Braakman HMH, Brimble E, Ruzhnikov MRZ, Wagner M, Harrer P, Wieczorek D, Kuechler A, Tziperman B, Barel O, de Vries BBA, Gordon CT, Janssens V, Vissers L (2019) De novo mutations affecting the catalytic calpha subunit of PP2A, PPP2CA, cause syndromic intellectual disability resembling other PP2A-related neurodevelopmental disorders. Am J Hum Genet 104:139–156. https://doi.org/10.1016/j.ajhg.2018.12.002CrossRefPubMed

12.

Watkins GR, Wang N, Mazalouskas MD, Gomez RJ, Guthrie CR, Kraemer BC, Schweiger S, Spiller BW, Wadzinski BE (2012) Monoubiquitination promotes calpain cleavage of the protein phosphatase 2A (PP2A) regulatory subunit alpha4, altering PP2A stability and microtubule-associated protein phosphorylation. J Biol Chem 287:24207–24215. https://doi.org/10.1074/jbc.M112.368613CrossRefPubMedPubMedCentral

13.

Okamura H, Yoshida K, Yang D, Haneji T (2013) Protein phosphatase 2A Calpha regulates osteoblast differentiation and the expressions of bone sialoprotein and osteocalcin via osterix transcription factor. J Cell Physiol 228:1031–1037. https://doi.org/10.1002/jcp.24250CrossRefPubMed

14.

von Brevern M, Radtke A, Lezius F, Feldmann M, Ziese T, Lempert T, Neuhauser H (2007) Epidemiology of benign paroxysmal positional vertigo: a population based study. J Neurol Neurosurg Psychiatry 78:710–715. https://doi.org/10.1136/jnnp.2006.100420CrossRef

15.

Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group Osteoporos Int 4:368–381. https://doi.org/10.1007/BF01622200CrossRef

16.

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605. https://doi.org/10.1007/s10654-010-9491-zCrossRefPubMed

17.

Deeks JJ, Macaskill P, Irwig L (2005) The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 58:882–893. https://doi.org/10.1016/j.jclinepi.2005.01.016CrossRefPubMed

18.

Lu XD, Han WX, Liu YX (2019) Suppression of miR-451a accelerates osteogenic differentiation and inhibits bone loss via Bmp6 signaling during osteoporosis. Biomed Pharmacother 120:109378. https://doi.org/10.1016/j.biopha.2019.109378CrossRefPubMed

19.

Yoon S, Kook T, Min HK, Kwon DH, Cho YK, Kim M, Shin S, Joung H, Jeong SH, Lee S, Kang G, Park Y, Kim YS, Ahn Y, McMullen JR, Gergs U, Neumann J, Kim KK, Kim J, Nam KI, Kim YK, Kook H, Eom GH (2018) PP2A negatively regulates the hypertrophic response by dephosphorylating HDAC2 S394 in the heart. Exp Mol Med 50:1–14. https://doi.org/10.1038/s12276-018-0121-2CrossRefPubMedPubMedCentral

20.

Zhou X, Geng L, Wang D, Yi H, Talmon G, Wang J (2017) R-spondin1/LGR5 activates TGFbeta signaling and suppresses colon cancer metastasis. Cancer Res 77:6589–6602. https://doi.org/10.1158/0008-5472.CAN-17-0219CrossRefPubMedPubMedCentral

21.

Huss D, Dickman JD (2003) Histological preparation of developing vestibular otoconia for scanning electron microscopy. J Neurosci Methods 125:129–136. https://doi.org/10.1016/s0165-0270(03)00048-7CrossRefPubMed

22.

Liu Z, Yoshimi A, Wang J, Cho H, Chun-Wei Lee S, Ki M, Bitner L, Chu T, Shah H, Liu B, Mato AR, Ruvolo P, Fabbri G, Pasqualucci L, Abdel-Wahab O, Rabadan R (2020) Mutations in the RNA splicing factor SF3B1 promote tumorigenesis through MYC stabilization. Cancer Discov 10:806–821. https://doi.org/10.1158/2159-8290.CD-19-1330CrossRefPubMedPubMedCentral

23.

Dror AA, Taiber S, Sela E, Handzel O, Avraham KB (2020) A mouse model for benign paroxysmal positional vertigo with genetic predisposition for displaced otoconia. Genes Brain Behav 19:e12635. https://doi.org/10.1111/gbb.12635CrossRefPubMedPubMedCentral

24.

Kim SY, Kim HJ, Min C, Choi HG (2020) Association between benign paroxysmal positional vertigo and osteoporosis: two nested case-control studies. Osteoporos Int 31:2017–2024. https://doi.org/10.1007/s00198-020-05478-xCrossRefPubMed

25.

Byun H, Chung JH, Lee SH, Park CW, Kim EM, Kim I (2019) Increased risk of benign paroxysmal positional vertigo in osteoporosis: a nationwide population-based cohort study. Sci Rep 9:3469. https://doi.org/10.1038/s41598-019-39830-xCrossRefPubMedPubMedCentral

26.

Bruintjes TD, van der Zaag-Loonen HJ, Eggelmeijer F, van Leeuwen RB (2018) The prevalence of benign paroxysmal positional vertigo in patients with osteoporosis. Eur Arch Otorhinolaryngol 275:3083–3086. https://doi.org/10.1007/s00405-018-5164-4CrossRefPubMed

27.

Yu S, Liu F, Cheng Z, Wang Q (2014) Association between osteoporosis and benign paroxysmal positional vertigo: a systematic review. BMC Neurol 14:110. https://doi.org/10.1186/1471-2377-14-110CrossRefPubMedPubMedCentral

28.

Choi HG, Lee JK, Kong IG, Lim H, Kim SY (2019) Osteoporosis increases the risk of benign paroxysmal positional vertigo: a nested case-control study using a national sample cohort. Eur Arch Otorhinolaryngol 276:335–342. https://doi.org/10.1007/s00405-018-5230-yCrossRefPubMed

29.

Pan X, Chen X, Tong X, Tang C, Li J (2015) Ppp2ca knockout in mice spermatogenesis. Reproduction 149:385–391. https://doi.org/10.1530/REP-14-0231CrossRefPubMed

30.

Okamura H, Yang D, Yoshida K, Haneji T (2013) Protein phosphatase 2A Calpha is involved in osteoclastogenesis by regulating RANKL and OPG expression in osteoblasts. FEBS Lett 587:48–53. https://doi.org/10.1016/j.febslet.2012.10.041CrossRefPubMed

31.

Yang C, Ren J, Li B, Jin C, Ma C, Cheng C, Sun Y, Shi X (2019) Identification of gene biomarkers in patients with postmenopausal osteoporosis. Mol Med Rep 19:1065–1073. https://doi.org/10.3892/mmr.2018.9752CrossRefPubMed

32.

Mao Z, Zhu Y, Hao W, Chu C, Su H (2019) MicroRNA-155 inhibition up-regulates LEPR to inhibit osteoclast activation and bone resorption via activation of AMPK in alendronate-treated osteoporotic mice. IUBMB Life 71:1916–1928. https://doi.org/10.1002/iub.2131CrossRefPubMed

33.

Moriishi T, Kawai Y, Komori H, Rokutanda S, Eguchi Y, Tsujimoto Y, Asahina I, Komori T (2014) Bcl2 deficiency activates FoxO through Akt inactivation and accelerates osteoblast differentiation. PLoS ONE 9:e86629. https://doi.org/10.1371/journal.pone.0086629CrossRefPubMedPubMedCentral

34.

Ryan SS, Eastman A (2016) BCL2 inhibitors as anticancer drugs: a plethora of misleading BH3 mimetics. Mol Cancer Ther 15:2011–2017. https://doi.org/10.1158/1535-7163.MCT-16-0031CrossRef

35.

Leverson JD, Sampath D, Souers AJ, Rosenberg SH, Fairbrother WJ, Amiot M, Konopleva M, Letai A (2017) Found in translation: how preclinical research is guiding the clinical development of the BCL2-selective inhibitor venetoclax. Cancer Discov 7:1376–1393. https://doi.org/10.1158/2159-8290.CD-17-0797CrossRefPubMedPubMedCentral

36.

Siddiqui WA, Ahad A, Ahsan H (2015) The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update. Arch Toxicol 89:289–317. https://doi.org/10.1007/s00204-014-1448-7CrossRef

Title: Relationship between osteoporosis and benign paroxysmal positional vertigo based on evidence-based medicine and bioinformatics
Authors: Tuanmao Guo
Yanli Xing
Haiyun Zhu
Lan Yang
Yuan Xiao
Jiang Xu
Publication date: 01-12-2021
Publisher: Springer London
Keywords: Benign Paroxysmal Positional Vertigo
Osteoporosis
Osteoporosis
Published in: Archives of Osteoporosis / Issue 1/2021
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI: https://doi.org/10.1007/s11657-021-01006-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Relationship between osteoporosis and benign paroxysmal positional vertigo based on evidence-based medicine and bioinformatics

Abstract

Summary

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Accounts of health risk assessment survey administration in the Catch a Break Program: the social construction of osteoporosis risk identification and need for intervention

Age-related trends and reference intervals of cross-linked C-telopeptide of type I collagen and procollagen type I N-propeptide from a reference population of Sri Lankan adult women

Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf Cooperation Council countries

Maternal vitamin D and offspring fracture risk: the Vitamin D in Pregnancy study

Cost-effectiveness of sequential daily teriparatide/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan

Age-related changes and reference intervals of RANKL, OPG, and bone turnover markers in Indian women